 |
 INTEGRASE STRAND TRANSFER INHIBITORS
| |
Mutations associated with resistance |
Mutations associated with "possible resistance" |
RAL
|
T66A/K [10,40]
E92Q [1, 2]
G118R [10,17]
F121Y [10,17]
G140A/S [7]
Y143A/C/G/H/R/S [1, 3, 4, 5, 8, 14]
N144D [42]
Q148E/G/H/K/R [1, 2]
V151L [9]
N155H/S/T [1, 2, 9]
E157Q [2]
S230R [18, 31, 32, 33]
R263K [16,18]
L74F/I + V75I [36]
|
|
| EVG |
T66A/I/K [6]
E92Q [6]
T97A [19, 20]
G118R [17]
F121Y [9,17]
E138K
G140A/C/S [34, 41]
Y143A/C/G/H/R/S [14]
N144D [42]
P145S [9]
S147G [19]
Q148E/G/H/K/R [6]
V151L [9]
N155H/S/T [6, 9]
E157Q [11,35]
S230R [18, 31, 32, 33]
R263K [18]
L74F/I + V75I [36] |
|
DTG*
50 mg BID
50 mg QD |
G118R [12,13]
F121Y [17]
N144D [42]
V151L [9,23]
S153F/Y [9, 23, 26, 34]
R263K [16]
T66K + L74M [9]
E92Q + N155H [9, 21, 22]
Q148H/K/R + at least 2 mutations among: L74I or T97A or E138A/K/T or G140A/C/S [15, 38, 39]
Q148H/K/R + N155H [9, 27,28]
G118R [12,13]
F121Y [17]
E138A/K/T [15]
G140A/C/S [15]
N144D [42]
Q148H/K/R
V151L [9, 23]
S153F/Y [9, 23, 26, 34]
N155H [18]
S230R [29]
R263K [16]
T66K + L74M [9]
L74I + E92Q [30]
|
T66K [9]
Q148H/K/R + 1 mutation among: L74I or E138A/K/T or G140A/C/S [15]
T66K [9] |
| CAB** |
G118R [12,13]
F121Y [17]
E138A/K/T
G140A/C/R/S [37]
N144D [42]
Q148H/K/R [15]
V151L [9, 23]
S153F/Y [9, 23, 26, 34]
N155H [18]
S230R [29]
R263K [16]
T66K + L74M [9]
L74I + E92Q [30]
|
T66K [9]
|
| BIC** |
G118R [12,13]
F121Y [17]
E138A/K/T
G140A/C/S
N144D [42]
Q148H/K/R
V151L [9, 23]
S153F/Y [9, 23, 26, 34]
N155H [18]
S230R [29]
R263K [16]
T66K + L74M [9]
L74I + E92Q [30]
|
T66K [9]
|
RAL: raltegravir, EVG: elvitegravir, DTG: dolutegravir, CAB: cabotegravir, BIC: bictegravir.
* Please note that rules are different for DTG 50 mg BID and 50 mg QD.
**Due to few data and to the very close structures of dolutegravir, cabotegravir and bictegravir some rules for dolutegravir QD are transposed to cabotegravir and bictegravir.
For DNA provirus, impact of stop codons and G->A mutations on ARV resistance is unknown
References
|
|
